EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Otsuka, K. [1 ]
Hata, A. [2 ]
Kato, R. [1 ]
Takeshita, J. [1 ]
Okuda, C. [1 ]
Kaji, R. [1 ]
Masago, K. [1 ]
Fujita, S. [1 ]
Katakami, N. [3 ]
机构：
[1] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan
[2] Inst Biomed Res & Innovat Hosp, Kobe, Hyogo, Japan
[3] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu349.65
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1286P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [2] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [3] MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
    Felip, E.
    Minotti, V.
    Soo, R.
    Wolf, J.
    Solomon, B.
    Tan, D. S. W.
    Ardizzoni, A.
    Lee, D. H.
    Sequist, L. V.
    Barlesi, F.
    Paz-Ares, L.
    Rodriguez-Abreu, D.
    Garcia Campelo, M. R.
    Sprauten, M.
    Djentuh, L. O'Sullivan
    Belli, R.
    Glaser, S.
    Zou, M.
    Giovannini, M.
    Yang, J. C-H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S829 - S830
  • [4] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
  • [5] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [6] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [7] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    [J]. CANCERS, 2019, 11 (07)
  • [8] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Kimio Yonesaka
    Eiji Iwama
    Hidetoshi Hayashi
    Shinichiro Suzuki
    Ryoji Kato
    Satomi Watanabe
    Takayuki Takahama
    Junko Tanizaki
    Kaoru Tanaka
    Masayuki Takeda
    Kazuko Sakai
    Koichi Azuma
    Yasutaka Chiba
    Shinji Atagi
    Kazuto Nishio
    Isamu Okamoto
    Kazuhiko Nakagawa
    [J]. Scientific Reports, 9
  • [9] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Yonesaka, Kimio
    Iwama, Eiji
    Hayashi, Hidetoshi
    Suzuki, Shinichiro
    Kato, Ryoji
    Watanabe, Satomi
    Takahama, Takayuki
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Sakai, Kazuko
    Azuma, Koichi
    Chiba, Yasutaka
    Atagi, Shinji
    Nishio, Kazuto
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [10] Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer
    Sierra, Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (03)
12345